.Nature Medicine, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after a median consequence of 11 months, individuals along with metastatic intestinal tumors that got biomarker-matched therapies based upon distributing growth DNA profiling presented a greater scientific benefit than those acquiring incomparable treatment.